KemPharm Inc (KMPH) Receives Consensus Recommendation of “Buy” from Analysts
KemPharm Inc (NASDAQ:KMPH) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $9.25.
Several equities research analysts have recently issued reports on KMPH shares. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Wednesday, November 15th. Royal Bank of Canada set a $9.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, ValuEngine upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
In other KemPharm news, EVP Daniel L. Cohen acquired 7,500 shares of KemPharm stock in a transaction that occurred on Monday, November 27th. The stock was acquired at an average cost of $3.79 per share, for a total transaction of $28,425.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 22.80% of the stock is currently owned by insiders.
Shares of KemPharm (NASDAQ KMPH) traded up $0.15 during mid-day trading on Tuesday, hitting $5.80. 117,996 shares of the stock traded hands, compared to its average volume of 123,007. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. KemPharm has a 12 month low of $2.45 and a 12 month high of $6.75. The stock has a market cap of $84.99, a price-to-earnings ratio of -2.20 and a beta of -0.08.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/02/18/kempharm-inc-kmph-receives-consensus-recommendation-of-buy-from-analysts.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.